These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12715751)

  • 1. Strattera approved to treat ADHD.
    FDA Consum; 2003; 37(2):4. PubMed ID: 12715751
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.
    Waxmonsky JG
    Essent Psychopharmacol; 2005; 6(5):262-76. PubMed ID: 16222911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clip & save: drug chart. FDA-approved drugs to treat ADHD.
    J Psychosoc Nurs Ment Health Serv; 2010 Mar; 48(3):9-10. PubMed ID: 20302260
    [No Abstract]   [Full Text] [Related]  

  • 4. [Atomoxetine for the treatment of attention-deficit/hyperactivity disorder].
    Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Oct; 72(10):586-91. PubMed ID: 15472782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA-approved drugs to treat ADHD.
    J Psychosoc Nurs Ment Health Serv; 2012 Mar; 50(3):11-2. PubMed ID: 22390784
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atomoxetine in the treatment of attention deficit hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Daughton JM; Mayfield-Jorgensen ML; Burke WJ
    Expert Rev Neurother; 2004 Jul; 4(4):601-11. PubMed ID: 15853579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-stimulant trials of adult ADHD.
    Adler LA
    CNS Spectr; 2007 Apr; 12(4 Suppl 6):11-3. PubMed ID: 17717871
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating adult attention deficit hyperactivity disorder in hospitalized psychiatric patients.
    Castaneda R; Levy R; Hazzi C; Ross S; Roman W; Hamid H
    Gen Hosp Psychiatry; 2008; 30(6):572-7. PubMed ID: 19061685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
    Eiland LS; Guest AL
    Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological treatments for ADHD and the novel agent atomoxetine.
    Bailey KP
    J Psychosoc Nurs Ment Health Serv; 2003 Aug; 41(8):12-7. PubMed ID: 13677007
    [No Abstract]   [Full Text] [Related]  

  • 12. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
    Adler LA; Sutton VK; Moore RJ; Dietrich AP; Reimherr FW; Sangal RB; Saylor KE; Secnik K; Kelsey DK; Allen AJ
    J Clin Psychopharmacol; 2006 Dec; 26(6):648-52. PubMed ID: 17110824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database.
    Winterstein AG; Gerhard T; Shuster J; Zito J; Johnson M; Liu H; Saidi A
    Ann Pharmacother; 2008 Jan; 42(1):24-31. PubMed ID: 18042808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discussion on integrated pharmacologic treatment of attention-deficit hyperactivity disorder (ADHD).
    Hendren RL
    Essent Psychopharmacol; 2005; 6(5):291-300. PubMed ID: 16222913
    [No Abstract]   [Full Text] [Related]  

  • 15. Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD.
    Faraone SV; Wigal SB; Hodgkins P
    J Atten Disord; 2007 Jul; 11(1):74-82. PubMed ID: 17606774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The latest drugs on the FDA's radar.
    Waldron T
    Behav Healthc; 2006 Jun; 26(6):34-5. PubMed ID: 16833213
    [No Abstract]   [Full Text] [Related]  

  • 17. A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder.
    Wigal SB; McGough JJ; McCracken JT; Biederman J; Spencer TJ; Posner KL; Wigal TL; Kollins SH; Clark TM; Mays DA; Zhang Y; Tulloch SJ
    J Atten Disord; 2005 Aug; 9(1):275-89. PubMed ID: 16371674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyskinesias associated with atomoxetine in combination with other psychoactive drugs.
    Bond GR; Garro AC; Gilbert DL
    Clin Toxicol (Phila); 2007; 45(2):182-5. PubMed ID: 17364639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine (Strattera) revisited.
    Med Lett Drugs Ther; 2004 Aug; 46(1189):65. PubMed ID: 15314585
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.